Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Dimesylate, Lis-dexamfetamine
2. Dimesylate, Lisdexamfetamine
3. Elvanse
4. Lis Dexamfetamine Dimesylate
5. Lis-dexamfetamine Dimesylate
6. Lisdexamfetamine
7. Nrp 104
8. Nrp-104
9. Nrp104
10. Vyvanse
1. Vyvanse
2. 608137-33-3
3. Nrp-104
4. Lisdexamfetamine Mesilate
5. Spd489
6. Tyvense
7. Nrp104
8. Spd-489
9. Lisdexamfetamine Dimesylate [usan]
10. Lisdexamfetamine Dimesilate
11. Sjt761gegs
12. Lisdexamphetamine Dimesilate
13. L-lysine-d-amphetamine Dimesylate
14. Lisdexamfetamine Dimethanesulfonate
15. (2s)-2,6-diamino-n-[(1s)-1-methyl-2-phenylethyl]hexanamide Dimethanesulfonate
16. Lis-dexamfetamine Dimesylate
17. Lisdexamfetamine Mesilate (jan)
18. Lisdexamfetamine Dimesylate (usan)
19. Lisdexamfetamine Mesylate
20. Nrp 104
21. Lisdexamfetamine Mesilate [jan]
22. (2s)-2,6-diamino-n-[(2s)-1-phenylpropan-2-yl]hexanamide;methanesulfonic Acid
23. Unii-sjt761gegs
24. Venvanse
25. (2s)-2,6-diamino-n-((1s)-1-methyl-2-phenylethyl)hexanamide Dimethanesulfonate
26. Lys-amp
27. Spd 489
28. Lys-d-amp
29. Elvanse (tn)
30. Vyvanse (tn)
31. Schembl678421
32. Chembl1201178
33. Dtxsid60209653
34. Lisdexamfetamine Dimesylate Solution
35. Bcp24044
36. Akos030254940
37. Lisdexamfetamine Mesilate [mart.]
38. Ldx
39. Lisdexamfetamine Mesilate [who-dd]
40. Lisdexamfetamine Dimesylate [vandf]
41. D04747
42. Lisdexamfetamine Dimethanesulfonate [mi]
43. Lisdexamfetamine Dimesylate [orange Book]
44. 137l333
45. Q27289243
46. (2s)-2,6-diamino-n-((1s)-1-methyl-2-phenylethyl)hexanamide Dimethanesulphonate
47. Hexanamide, 2,6-diamino-n-((1s)-1-methyl-2-phenylethyl), (2s), Dimethanesulfonate
48. Hexanamide, 2,6-diamino-n-((1s)-1-methyl-2-phenylethyl), (2s), Dimethanesulphonate
49. Ldx;lisdexamfetamine Mesilate;lisdexamfetamine Mesylate;nrp 104;nrp-104;spd 489
50. Lisdexamfetamine Dimesylate Solution, 1.0 Mg/ml In Methanol (as Free Base), Ampule Of 1 Ml, Certified Reference Material
Molecular Weight | 455.6 g/mol |
---|---|
Molecular Formula | C17H33N3O7S2 |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 8 |
Exact Mass | 455.17599275 g/mol |
Monoisotopic Mass | 455.17599275 g/mol |
Topological Polar Surface Area | 207 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 344 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
1 of 4 | |
---|---|
Drug Name | Lisdexamfetamine dimesylate |
Drug Label | Vyvanse (lisdexamfetamine dimesylate), a CNS stimulant,isa capsule for once-a-day oral administration. The chemical designation for lisdexamfetamine dimesylate is (2S)-2,6-diamino-N-[(1S)-1-methyl-2-phenylethyl] hexanamide dimethanesulfonate.... |
Active Ingredient | Lisdexamfetamine dimesylate |
Dosage Form | Capsule |
Route | Oral |
Strength | 30mg; 50mg; 60mg; 40mg; 70mg; 20mg |
Market Status | Tentative Approval |
Company | Mylan Pharms; Amneal Pharms; Roxane |
2 of 4 | |
---|---|
Drug Name | Vyvanse |
PubMed Health | Amphetamine (By mouth) |
Drug Classes | Amphetamine |
Drug Label | Vyvanse (lisdexamfetamine dimesylate), a CNS stimulant,isa capsule for once-a-day oral administration. The chemical designation for lisdexamfetamine dimesylate is (2S)-2,6-diamino-N-[(1S)-1-methyl-2-phenylethyl] hexanamide dimethanesulfonate.... |
Active Ingredient | Lisdexamfetamine dimesylate |
Dosage Form | Capsule |
Route | Oral |
Strength | 30mg; 50mg; 60mg; 40mg; 20mg; 70mg |
Market Status | Prescription |
Company | Shire Development |
3 of 4 | |
---|---|
Drug Name | Lisdexamfetamine dimesylate |
Drug Label | Vyvanse (lisdexamfetamine dimesylate), a CNS stimulant,isa capsule for once-a-day oral administration. The chemical designation for lisdexamfetamine dimesylate is (2S)-2,6-diamino-N-[(1S)-1-methyl-2-phenylethyl] hexanamide dimethanesulfonate.... |
Active Ingredient | Lisdexamfetamine dimesylate |
Dosage Form | Capsule |
Route | Oral |
Strength | 30mg; 50mg; 60mg; 40mg; 70mg; 20mg |
Market Status | Tentative Approval |
Company | Mylan Pharms; Amneal Pharms; Roxane |
4 of 4 | |
---|---|
Drug Name | Vyvanse |
PubMed Health | Amphetamine (By mouth) |
Drug Classes | Amphetamine |
Drug Label | Vyvanse (lisdexamfetamine dimesylate), a CNS stimulant,isa capsule for once-a-day oral administration. The chemical designation for lisdexamfetamine dimesylate is (2S)-2,6-diamino-N-[(1S)-1-methyl-2-phenylethyl] hexanamide dimethanesulfonate.... |
Active Ingredient | Lisdexamfetamine dimesylate |
Dosage Form | Capsule |
Route | Oral |
Strength | 30mg; 50mg; 60mg; 40mg; 20mg; 70mg |
Market Status | Prescription |
Company | Shire Development |
Treatment of Attention Deficit Hyperactivity Disorder (ADHD)
Central Nervous System Stimulants
A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. (See all compounds classified as Central Nervous System Stimulants.)
Dopamine Uptake Inhibitors
Drugs that block the transport of DOPAMINE into axon terminals or into storage vesicles within terminals. Most of the ADRENERGIC UPTAKE INHIBITORS also inhibit dopamine uptake. (See all compounds classified as Dopamine Uptake Inhibitors.)
GDUFA
DMF Review : Reviewed
Rev. Date : 2020-01-28
Pay. Date : 2020-01-21
DMF Number : 22442
Submission : 2009-01-27
Status : Active
Type : II
NDC Package Code : 49812-0186
Start Marketing Date : 2012-01-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
GDUFA
DMF Review : Reviewed
Rev. Date : 2021-12-30
Pay. Date : 2021-11-18
DMF Number : 35645
Submission : 2021-11-23
Status : Active
Type : II
NDC Package Code : 51634-2058
Start Marketing Date : 2021-12-10
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Tofigh Daru develops & synthesizes a diverse range of APIs in Anticancer, Narcotics, Cardiovascular to Immunomodulatory Segments.
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-11-21
Pay. Date : 2023-10-12
DMF Number : 38874
Submission : 2023-10-20
Status : Active
Type : II
NDC Package Code : 49812-0186
Start Marketing Date : 2012-01-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-07-02
Pay. Date : 2018-05-22
DMF Number : 32289
Submission : 2018-05-18
Status : Active
Type : II
NDC Package Code : 61960-0300
Start Marketing Date : 2018-03-21
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36325
Submission : 2021-10-25
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38667
Submission : 2023-08-03
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2020-07-28
Pay. Date : 2020-06-03
DMF Number : 34823
Submission : 2020-05-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32210
Submission : 2017-11-22
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2020-01-28
Pay. Date : 2020-01-21
DMF Number : 22442
Submission : 2009-01-27
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-11-21
Pay. Date : 2023-10-12
DMF Number : 38874
Submission : 2023-10-20
Status : Active
Type : II
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
GDUFA
DMF Review : Complete
Rev. Date : 2021-12-30
Pay. Date : 2021-11-18
DMF Number : 35645
Submission : 2021-11-23
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36325
Submission : 2021-10-25
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38667
Submission : 2023-08-03
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20103
Submission : 2006-12-29
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-07-02
Pay. Date : 2018-05-22
DMF Number : 32289
Submission : 2018-05-18
Status : Active
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35754
Submission : 2021-05-28
Status : Active
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
GDUFA
DMF Review : Complete
Rev. Date : 2020-07-28
Pay. Date : 2020-06-03
DMF Number : 34823
Submission : 2020-05-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32210
Submission : 2017-11-22
Status : Inactive
Type : II
Lisdexamphetamine dimesilate INH
Date of Issue : 2022-09-01
Valid Till : 2025-07-28
Written Confirmation Number : WC-0046
Address of the Firm : Plot No. E-21, E-22/1, MIDC, Mahad, Dist. Raigad-402 309, Maharashtra
Lisdexamfetamine Dimesylate IH
Date of Issue : 2022-06-03
Valid Till : 2025-05-27
Written Confirmation Number : WC-0003
Address of the Firm : Vill.- Bhagwanpur, Barwala Road, Near Dera Bassi, Distt.- SAS Nagar (Mohali), Pu...
NDC Package Code : 49812-0186
Start Marketing Date : 2012-01-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
NDC Package Code : 51634-2058
Start Marketing Date : 2021-12-10
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 17180-1100
Start Marketing Date : 2007-02-23
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (18kg/18kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 59116-3013
Start Marketing Date : 2016-10-14
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 59116-3010
Start Marketing Date : 2012-10-26
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 59116-3012
Start Marketing Date : 2014-01-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 59116-3011
Start Marketing Date : 2013-07-02
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 61960-0300
Start Marketing Date : 2018-03-21
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65392-0118
Start Marketing Date : 2007-02-23
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 53834-401
Start Marketing Date : 2023-10-30
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
About the Company : Veranova is a global leader in the development and manufacturing of specialist and complex APIs for pharma and biotech customers. We have over 50 years of experience navigating the...
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
About the Company : Founded in 1979, Noramco specializes in the development and manufacturing of APIs for both opioid and non-opioid products. With expertise in controlled substance development and ma...
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
About the Company : Cohance Lifesciences is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialzation. With our...
Tofigh Daru develops & synthesizes a diverse range of APIs in Anticancer, Narcotics, Cardiovascular to Immunomodulatory Segments.
About the Company : Tofigh Daru (TODACO) belongs to the Tamin Pharmaceutical Investment Company, the biggest pharmaceutical holding in Iran. TODACO develops novel APIs in therapeutic categories like A...
About the Company : Back in the year 1973, a team of individuals came up with such an idea – The idea called Alkem. Looking back at our 5 decades, illustrious journey, that one small idea has Not on...
About the Company : Established in 2016, a state-of-the-art R&D facility engaged in the development of Novel processes for Bulk Actives including Deuterated Actives, Advanced Intermediates and up the ...
About the Company : Chr. Olesen Synthesis is a Danish manufacturer of APIs and advanced intermediates. Chr. Olesen Synthesis was established in 2012 after the Chr. Olesen Group acquisition of the mult...
About the Company : Embio is today the world’s second largest Integrated manufacturer of Ephedrine and Pseudoephedrine salts Embio’s facility at Mahad ( 180 Kms from Bombay by road ) has been au...
About the Company : J&H CHEM is one of China's leading providers of integrated fine chemical services including offering, research and development, Custom manufacturing business, as well as other Valu...
About the Company : As an internationally renowned outsourcing partner, we offer products and tailor-made service packages that are seamlessly embedded in the value chain of our customers. Our pharmac...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
RLD : No
TE Code : AB
Brand Name : LISDEXAMFETAMINE DIMESYLATE
Dosage Form : CAPSULE;ORAL
Dosage Strength : 50MG
Approval Date : 2023-08-25
Application Number : 214547
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : LISDEXAMFETAMINE DIMESYLATE
Dosage Form : CAPSULE;ORAL
Dosage Strength : 20MG
Approval Date : 2023-08-25
Application Number : 202830
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : LISDEXAMFETAMINE DIMESYLATE
Dosage Form : CAPSULE;ORAL
Dosage Strength : 40MG
Approval Date : 2023-08-25
Application Number : 202830
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : LISDEXAMFETAMINE DIMESYLATE
Dosage Form : CAPSULE;ORAL
Dosage Strength : 50MG
Approval Date : 2023-08-25
Application Number : 216944
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : LISDEXAMFETAMINE DIMESYLATE
Dosage Form : CAPSULE;ORAL
Dosage Strength : 10MG
Approval Date : 2023-08-25
Application Number : 211840
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : LISDEXAMFETAMINE DIMESYLATE
Dosage Form : TABLET, CHEWABLE;ORAL
Dosage Strength : 10MG
Approval Date : 2024-02-02
Application Number : 218306
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : LISDEXAMFETAMINE DIMESYLATE
Dosage Form : CAPSULE;ORAL
Dosage Strength : 10MG
Approval Date : 2023-08-25
Application Number : 216266
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code :
Brand Name : LISDEXAMFETAMINE DIMESYLATE
Dosage Form : CAPSULE;ORAL
Dosage Strength : 20MG
Approval Date : 2024-07-26
Application Number : 202836
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AB
Brand Name : LISDEXAMFETAMINE DIMESYLATE
Dosage Form : TABLET, CHEWABLE;ORAL
Dosage Strength : 50MG
Approval Date : 2023-08-25
Application Number : 214134
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : Yes
TE Code : AB
Brand Name : VYVANSE
Dosage Form : CAPSULE;ORAL
Dosage Strength : 30MG
Approval Date : 2007-02-23
Application Number : 21977
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Dosage Form : Tablet
Grade : Oral
Application : Taste Masking
Excipient Details : Sucralose is used as taste masking excipient in various formulations such as tablet, capsule, suspension & liquid, etc.
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Application : Co-Processed Excipients
Excipient Details : Mannitol is a co-processed excipient with superior compactibility, lower disintegration time, and hygroscopicity.
Dosage Form : Tablet
Grade : Oral
Excipients by Applications
Global Sales Information
Market Place
Reply
23 Oct 2024
Reply
03 Sep 2024
Reply
17 Jan 2024
Reply
05 Sep 2023
Reply
15 Jun 2023
Reply
15 May 2021
Reply
19 Sep 2020
Reply
10 Sep 2019
Reply
19 Jul 2018
Patents & EXCLUSIVITIES
Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23
Brand Name : VYVANSE
Patent Number : 2527646
Filing Date : 2004-06-01
Strength per Unit : 60 mg
Dosage Form : Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23
Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23
Brand Name : VYVANSE
Patent Number : 2527646
Filing Date : 2004-06-01
Strength per Unit : 30 mg
Dosage Form : Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23
Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23
Brand Name : VYVANSE
Patent Number : 2527646
Filing Date : 2004-06-01
Strength per Unit : 50 mg
Dosage Form : Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23
Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23
Brand Name : VYVANSE
Patent Number : 2527646
Filing Date : 2004-06-01
Strength per Unit : 20 mg
Dosage Form : Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23
Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23
Brand Name : VYVANSE
Patent Number : 2527646
Filing Date : 2004-06-01
Strength per Unit : 40 mg
Dosage Form : Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23
Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23
Brand Name : VYVANSE
Patent Number : 2527646
Filing Date : 2004-06-01
Strength per Unit : 10mg
Dosage Form : CAPSULE
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23
Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23
Brand Name : VYVANSE
Patent Number : 2527646
Filing Date : 2004-06-01
Strength per Unit : 70 mg
Dosage Form : CAPSULE
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?